文献速递肝病消化道肿瘤与早癌

多组学基于脂肪酸降解途径识别肝细胞癌代谢亚型以指导个体化治疗

Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2023-08-07

本研究对41例肝细胞癌患者行RNA测序、PCR芯片、脂质组学、代谢组学和蛋白质组学分析,其中17例接受抗PD-1治疗,并分析约60个公共多组学数据集。基于脂肪酸降解通路鉴定出F1、F2、F3三个分子亚型,F1免疫抑制微环境高浸润且对YM-155、Alisertib、索拉非尼、抗PD-1、抗PD-L1及阿替利珠单抗联合贝伐珠单抗(T+A)敏感,F3对TACE敏感,F2对T+A潜在敏感,液体活检可初步诊断亚型。

要点

  • 基于脂肪酸降解通路可将肝细胞癌分为F1、F2、F3三个分子亚型。
  • F1亚型脂肪酸降解活性最低且免疫抑制微环境高浸润,对多种药物敏感。
  • F3亚型脂肪酸降解活性最高对TACE敏感,F2亚型对T+A潜在敏感。

核心结论

  • 基于脂肪酸降解通路鉴定出3个具有独特临床和生物学特征的亚型,可优化个体化治疗并辅助临床决策。
  • 提供初步证据表明脂肪酸降解亚型可通过液体活检诊断。

研究设计与样本

  • 对41例肝细胞癌患者行RNA测序、PCR芯片、脂质组学、代谢组学和蛋白质组学分析,其中17例接受抗PD-1治疗。
  • 行单细胞RNA测序探索肿瘤微环境,并分析近60个公共多组学数据集。
  • 在患者队列、人源异种移植模型和自发小鼠模型中评估脂肪酸降解亚型与索拉非尼、TACE、免疫检查点抑制剂疗效的关联。

主要发现

  • F1亚型脂肪酸降解活性最低且免疫抑制微环境高浸润,F3亚型脂肪酸降解活性最高,F2亚型介于F1与F3之间。
  • F1亚型对YM-155、Alisertib、索拉非尼、抗PD-1、抗PD-L1及阿替利珠单抗联合贝伐珠单抗(T+A)治疗敏感。
  • F3亚型对TACE敏感,F2亚型对T+A联合治疗潜在敏感。

关键数值与推荐

  • 脂肪酸降解亚型基于脂肪酸降解通路鉴定,分为F1、F2、F3三个亚型,具有临床、突变、表观遗传、代谢和免疫特征差异。
  • F1亚型脂肪酸降解活性最低,对YM-155、Alisertib、索拉非尼、抗PD-1、抗PD-L1及T+A敏感。
  • F3亚型脂肪酸降解活性最高,对TACE敏感。
  • F2亚型为F1与F3的中间状态,对T+A联合治疗潜在敏感。

临床怎么用

  • 作者认为脂肪酸降解亚型可优化个体化癌症治疗并辅助临床决策。
  • 作者提供初步证据表明脂肪酸降解亚型可通过液体活检诊断。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Molecular classification is a promising tool for prognosis prediction and optimizing precision therapy for HCC. Here, we aimed to develop a molecular classification of HCC based on the fatty acid degradation (FAD) pathway, fully characterize it, and evaluate its ability in guiding personalized therapy. APPROACH AND RESULTS: We performed RNA sequencing (RNA-seq), PCR-array, lipidomics, metabolomics, and proteomics analysis of 41 patients with HCC, in which 17 patients received anti-programmed cell death-1 (PD-1) therapy. Single-cell RNA sequencing (scRNA-seq) was performed to explore the tumor microenvironment. Nearly, 60 publicly available multiomics data sets were analyzed. The associations between FAD subtypes and response to sorafenib, transarterial chemoembolization (TACE), immune checkpoint inhibitor (ICI) were assessed in patient cohorts, patient-derived xenograft (PDX), and spontaneous mouse model ls. A novel molecular classification named F subtype (F1, F2, and F3) was identified based on the FAD pathway, distinguished by clinical, mutational, epigenetic, metabolic, and immunological characteristics. F1 subtypes exhibited high infiltration with immunosuppressive microenvironment. Subtype-specific therapeutic strategies were identified, in which F1 subtypes with the lowest FAD activities represent responders to compounds YM-155 and Alisertib, sorafenib, anti-PD1, anti-PD-L1, and atezolizumab plus bevacizumab (T + A) treatment, while F3 subtypes with the highest FAD activities are responders to TACE. F2 subtypes, the intermediate status between F1 and F3, are potential responders to T + A combinations. We provide preliminary evidence that the FAD subtypes can be diagnosed based on liquid biopsies. CONCLUSIONS: We identified 3 FAD subtypes with unique clinical and biological characteristics, which could optimize individual cancer patient therapy and help clinical decision-making.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Li B, Li Y, Zhou H, et al. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology. 2023. PMID: 37540187. doi:10.1097/HEP.0000000000000553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。